

Allergic rhinitis management

1. In adults $\geq 12y$ (pregnancy/children on p2)

BSACI 2017 (Clin Exp Allergy 2017;47:856), International consensus statement: Allergic Rhinitis 2023 (ICAR 2023;13(4):293-859)



Red Whale
GEMS
Guidelines & Evidence Made Simple

The ARIA classification looks at severity and frequency of symptoms. Severity is used to guide which treatment to start. In practice, most who present to primary care will have moderate/severe symptoms:


Severity guides the starting treatment

MILD <ul style="list-style-type: none">No 'troublesome' symptomsNo impact on sleepNo impact on daily activitiesNormal work/school	MODERATE/ SEVERE <ul style="list-style-type: none">Troublesome symptomsAbnormal sleepImpaired daily activitiesProblems at school or work
---	--

If MILD symptoms:
START TREATMENT
HERE

ICAR guidance recommends intranasal saline alongside other treatments: improves QOL/nasal symptoms; reduces antihistamine use; is safe

If MODERATE OR SEVERE symptoms:
START TREATMENT
HERE



Correct use of nasal corticosteroid spray IS ESSENTIAL:

- Gently blow nose. Shake container and look down
- Squeeze once (or twice, depending on dose, in different directions); using L hand for R nostril and vice versa helps avoid nasal septum, reducing nosebleeds
- Don't close opposite nostril
- Breathe gently through nose – DO NOT sniff (*this keeps the active drug on the nasal mucosa and stops it being swallowed, reducing systemic absorption*)
- Keep going – full benefits can take a few weeks!

Check use, concordance and dose

Nasal corticosteroid spray AND antihistamine
(inhaled better than oral)

When monotherapy has failed, evidence favours **intranasal steroids WITH intranasal antihistamines**: more rapid onset of action, more effective symptom relief than other options. See main article for details. Usually more cost-effective as separate inhalers than combined in a single device

Check use, concordance and dose. Depending on symptoms, consider following:

Persistent watery rhinorrhoea
Add nasal ipratropium spray

Eye symptoms
Add topical mast cell stabiliser, e.g. sodium cromoglicate or topical antihistamine drops

Nasal blockage
Add brief nasal decongestant (<7d)

Persistent itch/sneeze/rash
Switch to oral antihistamine with nasal ICS

Catarrh AND asthmatic
Add leukotriene receptor antagonist

Treatment failure

- Is the diagnosis correct? Could this be something else (see table at end of main article)?
- Refer for ENT opinion if structural issue suspected
- Still suspect allergic rhinitis? Consider referral for consideration of immunotherapy (effective only if one allergen is responsible for most symptoms)

What about oral steroids? Most symptoms can be managed without oral steroids, and the risks of adverse events can outweigh the benefits. ICAR recommends NOT to use oral steroids. BSACI says short-term oral steroids can be considered for very severe or intractable symptoms. The DTB suggests 0.5mg/kg for 5–10 days (DTB 2020;58(4):57).

What about intramuscular steroids? No! Intramuscular corticosteroid injections are effective, but can be associated with systemic side-effects and muscular and subcutaneous necrosis, and are not advised by BSACI 2017 or ICAR 2023.

We make every effort to ensure the information in these pages is accurate and correct at the date of publication, but it is of necessity of a brief and general nature. The information presented herein should not replace your own good clinical judgement, or be regarded as a substitute for taking professional advice in appropriate circumstances. In particular, we suggest you carefully consider the specific facts, circumstances and medical history of any patient, and recommendations of the relevant regulatory authorities. We also suggest that you check drug doses, potential side-effects and interactions with the British National Formulary. Save insofar as any such liability cannot be excluded at law, we do not accept any liability for loss of any type caused by reliance on the information in these pages. December 2023. For full references see the relevant Red Whale articles.

Allergic rhinitis management

2. Pregnancy or children (<12y)

BSACI 2017 (Clin Exp Allergy 2017;47:856), International consensus statement: Allergic Rhinitis 2023 (ICAR 2023;13(4):293-859)



Red Whale

GEMS

Guidelines & Evidence Made Simple

Management options in pregnancy and breastfeeding

Rhinitis affects at least 20% of pregnancies and falls into two groups:

- Women with a history of allergic rhinitis that continues in pregnancy.
- Women who develop pregnancy-induced rhinitis (this is self-limiting).

BSACI guidance (2017) advises that most medications cross the placenta, and recommends that they should only be prescribed if the benefits outweigh the risks.

- **Nasal lavage with saline** is safe and reduces the need for antihistamines.
- In the first trimester, nasal chromones such as sodium cromoglycate are the drug of choice as they have not shown teratogenic effects in animals – *but this is no longer available in the UK.*
- **Nasal steroids:** the safety of nasal steroids has not been established in clinical trials, BUT beclometasone, fluticasone propionate and budesonide have “good safety records” and are used widely in asthma in pregnancy. As a nasal spray, fluticasone propionate has the lowest bioavailability.
- **Antihistamines:** there is considerable clinical experience using chlorphenamine, loratadine and cetirizine in pregnancy, and these can be used in addition to the above measures if necessary. **When breastfeeding,** avoid chlorphenamine as this may cause infant drowsiness or poor feeding.
- **Decongestants should NOT be used.**
- **Immunotherapy:** women can continue immunotherapy if they have reached maintenance phase, but it should not be initiated or up-titrated during pregnancy (*this would be a secondary care decision*).

Management options in children <12y

Note: different drugs are licensed at different ages – see BNFc

Step-up therapy if symptoms poorly controlled. Consider referral for specific immunotherapy

Step-down therapy if symptoms well controlled

**Antihistamine
(oral or nasal)**

Nasal inhaled corticosteroid
Choose one with low bioavailability
(e.g. mometasone or fluticasone propionate), use lowest effective dose and monitor growth if long-term use (particularly if on multiple steroids)

Trial of **nasal inhaled corticosteroid AND antihistamine (oral or nasal)**
And, **ONLY if asthmatic, can consider leukotriene receptor antagonist (off-licence)**